Equity Research, Broker Reports, and media content on Amryt Pharma PLC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Amryt Pharma PLC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Amryt Pharma PLC

Company Profile

  • Personnel
  • Joe Wiley, CEO
  • Rory Nealon , CFO

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Amryt Pharma PLC. We currently have 115 research reports from 5 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 80.0/250p
  • Daily Volume: N/A
  • Daily Liquidity: (0.01%)
  • # Shares: 158.5m
  • Market Cap: £366.5m
  • Latest PE (hist):
  • Div Yield:
Date Source Announcement
20Jan21 07:00 GNW Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
06Jan21 07:00 RNS-R Amryt to present at H.C Wainwright Conference
23Dec20 07:00 GNW Amryt Granted Orphan Drug Designation by the FDA for AP103
17Dec20 07:00 GNW Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11Dec20 10:00 GNW Holding(s) in Company
09Dec20 14:45 GNW Holding(s) in Company
09Dec20 07:00 GNW Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
  • Frequency of research reports


  • Research reports on

    Amryt Pharma PLC

  • Providers covering

    Amryt Pharma PLC